Latest News

Caryn Sullivan, 48, is a wife and mother, and she is also a fighter. At 31 as a newlywed, she had her first breast cancer diagnosis after a lump was discovered.

Dr. Lajos Pusztai is a breast medical oncologist that specializes in caring for women with estrogen receptor-positive and-negative breast cancers and is well known for his research into genetics and genomics.

Dr. Sanft explains her role as a breast medical oncologist, as well as Director of the Survivorship Clinic and Patient Experience Officer.

An interview with Dr. Kerin Adelson is featured in the top five most-read oncology articles of 2020 at the American Journal of Managed Care.

Over two days, the top 22 biotech opportunities developing within Yale took the virtual stage to present their five-minute pitches to a panel of ten senior executives from biotech investment funds and pharmaceutical companies. Thank you to our sponsors, judges and an online audience of approximately 300 attendees from over 150 companies and investment firms.

In HER2-positive early stage (stage I-II) breast cancer, several different preoperative (also called neoadjuvant) chemotherapy options exist, each of these is associated with a different rate of complete eradication of cancer from the breast and lymph nodes (called pathologic complete response or pCR). Patients who experience pCR have excellent long term survival.

The common belief that tumors arise via activation of a few genes that “drive” cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center researchers.

A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.